Búsqueda | BVS Medicinas Tradicionales, Complementarias, e Integrativas en las Américas

1.

Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study.

Blijham, G; Wagener, T; Wils, J; de Greve, J; Buset, M; Bleiberg, H; Lacave, A; Dalmark, M; Selleslag, J; Collette, L; Sahmoud, T.

J Clin Oncol ; 14(8): 2266-73, 1996 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-8708716

2.

Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group.

Wils, J A; Klein, H O; Wagener, D J; Bleiberg, H; Reis, H; Korsten, F; Conroy, T; Fickers, M; Leyvraz, S; Buyse, M.

J Clin Oncol ; 9(5): 827-31, 1991 May.

Artículo en Inglés | MEDLINE | ID: mdl-2016625

3.

Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group.

Vanhoefer, U; Rougier, P; Wilke, H; Ducreux, M P; Lacave, A J; Van Cutsem, E; Planker, M; Santos, J G; Piedbois, P; Paillot, B; Bodenstein, H; Schmoll, H J; Bleiberg, H; Nordlinger, B; Couvreur, M L; Baron, B; Wils, J A.

J Clin Oncol ; 18(14): 2648-57, 2000 Jul.

Artículo en Inglés | MEDLINE | ID: mdl-10894863

4.

Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.

Conroy, T; Etienne, P L; Adenis, A; Wagener, D J; Paillot, B; François, E; Bedenne, L; Jacob, J H; Seitz, J F; Bleiberg, H; Van Pottelsberghe, C; Van Glabbeke, M; Delgado, F M; Merle, S; Wils, J.

J Clin Oncol ; 14(1): 164-70, 1996 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-8558192

5.

A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors.

Van Den Neste, E; de Valeriola, D; Kerger, J; Bleiberg, H; Kusenda, Z; Brassinne, C; Bartholomeus, S; Selleslags, J; Hennebert, P; Wythouck, H; Cazenave, I; Lefresne-Soulas, F; Piccart, M.

Clin Cancer Res ; 6(1): 64-71, 2000 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-10656433

6.

CPT-11 in gastrointestinal cancer.

Bleiberg, H.

Eur J Cancer ; 35(3): 371-9, 1999 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-10448285

7.

Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective.

Bleiberg, H; Cvitkovic, E.

Eur J Cancer ; 32A Suppl 3: S18-23, 1996.

Artículo en Inglés | MEDLINE | ID: mdl-8943661

8.

A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU)+leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas.

Caroli-Bosc, F X; Van Laethem, J L; Michel, P; Gay, F; Hendlisz, A; Forget, F; Bleiberg, H.

Eur J Cancer ; 37(15): 1828-32, 2001 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-11576835

9.

High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group.

Wils, J; Blijham, G H; Wagener, Th; De Greve, J; Jansen, R L H; Kok, T C; Nortier, J W R; Bleiberg, H; Couvreur, M L; Genicot, B; Baron, B.

Eur J Cancer ; 39(3): 346-52, 2003 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-12565987

10.

Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).

Van Cutsem, E; Cunningham, D; Ten Bokkel Huinink, W W; Punt, C J; Alexopoulos, C G; Dirix, L; Symann, M; Blijham, G H; Cholet, P; Fillet, G; Van Groeningen, C; Vannetzel, J M; Levi, F; Panagos, G; Unger, C; Wils, J; Cote, C; Blanc, C; Hérait, P; Bleiberg, H.

Eur J Cancer ; 35(1): 54-9, 1999 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-10211088

11.

Adjuvant radiotherapy and chemotherapy in resectable gastric cancer. A randomized trial of the gastro-intestinal tract cancer cooperative group of the EORTC.

Bleiberg, H; Goffin, J C; Dalesio, O; Buyse, M; Pector, J C; Gignoux, M; Roussel, A; Samana, G; Michel, J; Gerard, A.

Eur J Surg Oncol ; 15(6): 535-43, 1989 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-2689236

12.

[Adjuvant chemotherapy in cancers of the colon and rectum]. / Chimiothérapie adjuvante des cancers du côlon et du rectum.

Bleiberg, H.

Rev Prat ; 44(20): 2721-6, 1994 Dec 15.

Artículo en Francés | MEDLINE | ID: mdl-7878362

13.

A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer.

Bleiberg, H; Vandebroek, A; Deleu, I; Vergauwe, P; Rezaei Kalantari, H; D'Haens, G; Paesmans, M; Peeters, M; Efira, A; Humblet, Y.

Acta Gastroenterol Belg ; 75(1): 14-21, 2012 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-22567742

14.

Adjuvant treatment of colon cancer. A plea for a large-scale European trial.

Wils, J; Bleiberg, H; Rougier, P.

Eur J Cancer ; 30A(5): 578-9; discussion 579-80, 1994.

Artículo en Inglés | MEDLINE | ID: mdl-8080668

15.

Adjuvant therapy in high-risk colon cancer.

Bleiberg, H.

Semin Oncol ; 27(5 Suppl 10): 48-59, 2000 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-11049033

16.

CPT-11 (irinotecan) in the treatment of colorectal cancer: a new mechanism of action for additional activity.

Bleiberg, H.

Tumori ; 83(1 Suppl): S85-6, 1997.

Artículo en Inglés | MEDLINE | ID: mdl-9154078

17.

Treatment of advanced digestive non-colon cancer with a weekly 24-h infusion of high-dose 5-fluorouracil modulated by folinic acid and cisplatin: an easy-to-use and well-tolerated combination.

Delaunoit, T; Maréchal, R; Hendlisz, A; Eisendrath, P; Legendre, H; Pector, J C; De Becker, D; Bleiberg, H.

Anticancer Drugs ; 15(7): 725-8, 2004 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-15269605

18.

[Adjuvant treatment in cancer of the stomach]. / Les traitements adjuvants dans les cancers de l'estomac.

Popowski, G; Bleiberg, H; Van Houtte, P.

Acta Gastroenterol Belg ; 52(3-4): 382-8, 1989.

Artículo en Francés | MEDLINE | ID: mdl-2700274

19.

An EORTC gastrointestinal (GI) group randomized evaluation of the toxicity of sequential high dose methotrexate and 5-fluorouracil combined with adriamycin (FAMTX) vs 5-fluorouracil, adriamycin and mitomycin (FAM) in advanced gastric cancer.

Klein, H O; Wils, J; Bleiberg, H; Buyse, M; Duez, N.

Med Oncol Tumor Pharmacother ; 6(2): 171-4, 1989.

Artículo en Inglés | MEDLINE | ID: mdl-2664372

20.

Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.

Freyer, G; Rougier, P; Bugat, R; Droz, J P; Marty, M; Bleiberg, H; Mignard, D; Awad, L; Herait, P; Culine, S; Trillet-Lenoir, V.

Br J Cancer ; 83(4): 431-7, 2000 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-10945486

BVS Medicinas Tradicionales, Complementarias, e Integrativas en las Américas - MTCI

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study.

Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group.

Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.

A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors.

CPT-11 in gastrointestinal cancer.

Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective.

A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU)+leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas.

High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group.

Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).

Adjuvant radiotherapy and chemotherapy in resectable gastric cancer. A randomized trial of the gastro-intestinal tract cancer cooperative group of the EORTC.

[Adjuvant chemotherapy in cancers of the colon and rectum]. / Chimiothérapie adjuvante des cancers du côlon et du rectum.

A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer.

Adjuvant treatment of colon cancer. A plea for a large-scale European trial.

Adjuvant therapy in high-risk colon cancer.

CPT-11 (irinotecan) in the treatment of colorectal cancer: a new mechanism of action for additional activity.

Treatment of advanced digestive non-colon cancer with a weekly 24-h infusion of high-dose 5-fluorouracil modulated by folinic acid and cisplatin: an easy-to-use and well-tolerated combination.

[Adjuvant treatment in cancer of the stomach]. / Les traitements adjuvants dans les cancers de l'estomac.

An EORTC gastrointestinal (GI) group randomized evaluation of the toxicity of sequential high dose methotrexate and 5-fluorouracil combined with adriamycin (FAMTX) vs 5-fluorouracil, adriamycin and mitomycin (FAM) in advanced gastric cancer.

Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.